

Day : Tuesday
Date: 4/24/2007

Time: 13:42:43

 **PALM INTRANET**

Inventor Information for 10/517391

Inventor Name	City	State/Country
BASTIEN, PHILIPPE	CHARENTON LE PONT	FRANCE
JOURDAIN, ROLAND	MEUDON LA FORET	FRANCE
DE LACHARRIERE, OLIVIER	PARIS	FRANCE

[Appln Info](#)[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity/Reexam](#)[Foreign I](#)Search Another: Application# or Patent# PCT / / or PG PUBS # Attorney Docket # Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

US 20070092894 A1	US- PGPUB	20070426	Methods and kits for detecting single nucleotide polymorphisms of chromosome implicated in premature canities	435/6		De Lacharriere; Olivier et al.
US 20070065389 A1	US- PGPUB	20070322	Genes from chromosomes 3, 5 and 11 involved in premature canities	424/70.13	435/6; 514/44	De Lacharriere; Olivier et al.
US 20070012320 A1	US- PGPUB	20070118	Hair loss questionnaire system and method	128/898	705/3	De Lacharriere; Olivier et al.
US 20060122465 A1	US- PGPUB	20060608	Methods and systems for generating diagnostic algorithms based on questionnaires	600/300	128/920	Bastien; Philippe et al.
US 20060008453 A1	US- PGPUB	20060112	Methods and compositions for preventing and treating sensitive and dry skin	424/93.45		Breton; Lionel et al.
US 20050214821 A1	US- PGPUB	20050929	Chromosome 6 and 9 genes involved in premature canities	435/6	424/70.13	De Lacharriere, Olivier et al.
US 20050208010 A1	US- PGPUB	20050922	Genes from Chromosome 3, 5 and 11 involved in premature canities	424/70.13	514/44	De Lacharriere, Olivier et al.
US 20040116824 A1	US- PGPUB	20040617	Evaluation or diagnostic kit	600/556	424/9.2	Hirt, Jean-Pascal et al.
US 20040037776 A1	US- PGPUB	20040226	Non-therapeutic methods of evaluating skin neurosensitivity, kit and use of a kit for implementing the method	424/9.81		Lacharriere, Olivier De et al.
US 20040034610 A1	US- PGPUB	20040219	Methods involving artificial intelligence	706/20	706/25; 707/101	De Lacharriere, Olivier et al.
US 20030124084 A1	US- PGPUB	20030703	Use of dehydroepiandrosterone and/or precursors or derivatives thereof to improve papery aspect of the skin	424/74	424/757; 424/773; 514/178	De Lacharriere, Olivier et al.
US 20030064929 A1	US- PGPUB	20030403	Modulating body/cranial hair growth	514/12	424/70.122; 424/70.14; 435/192; 530/324	Duranton, Albert et al.
US	US-	20030227	Use of a composition	424/401	514/55;	De Lacharriere,

20030039669 A1	PGPUB		containing an effective quantity of at least one chelating agent for partially or totally reducing the symptoms associated with histamine release in the organism		514/6	Olivier et al.
US 20030026820 A1	US- PGPUB	20030206	Use of a composition containing an effective quantity of at least one ion chelating agent for increasing the tolerance threshold of a sensitive or intolerant skin	424/401	514/6	De Lacharriere, Olivier et al.
US 20020068072 A1	US- PGPUB	20020606	USE OF A SUBSTANCE P ANTAGONIST IN A PHARMACEUTICAL COMPOSITION	424/401	424/400	DE LACHARRIERE, OLIVIER et al.
US 20020037854 A1	US- PGPUB	20020328	USE OF AT LEAST ONE NO SYNTHASE INHIBITOR FOR TREATING SENSITIVE SKIN	514/18	514/19; 562/560	BRETON, LIONEL et al.
US 20010051157 A1	US- PGPUB	20011213	THERAPEUTIC/COSMETIC COMPOSITIONS COMPRISING CGRP ANTAGONISTS FOR TREATING SENSITIVE HUMAN SKIN	424/133.1	424/130.1; 424/158.1; 424/809; 514/2; 530/300; 530/387.1	BRETON, LIONEL et al.
US 20010028889 A1	US- PGPUB	20011011	Therapeutic/cosmetic compositions comprising bradykinin antagonists for treating sensitive human skin	424/401		Breton, Lionel et al.
US 6572848 B1	USPAT	20030603	Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins	424/78.02	424/401; 424/78.05; 424/78.07; 514/221; 514/275; 514/302; 514/353; 514/354; 514/355; 514/356; 514/561; 514/711; 514/864; 514/887	Breton; Lionel et al.

US 6509014 B1	USPAT	20030121	Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discreet erythema	424/130.1	514/2; 530/300; 530/350; 530/387.1	De Lacharriere; Olivier et al.
US 6471997 B1	USPAT	20021029	Iridaceae extract and compositions containing it	424/725	424/773; 424/774; 424/779	Breton; Lionel et al.
US 6465421 B1	USPAT	20021015	Modulating body/cranial hair growth	514/1	424/70.1; 514/169; 514/712; 514/715; 514/717; 514/880; 548/100; 554/1; 562/400	Duranton; Albert et al.
US 6416760 B2	USPAT	20020709	Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin	424/185.1	424/130.1; 424/133.1; 424/145.1; 424/158.1; 424/198.1;	Breton; Lionel et al.
					514/2; 530/300; 530/387.1	
US 6344438 B1	USPAT	20020205	Therapeutic/cosmetic compositions comprising CGRP antagonists for treating the eyes or eyelids	514/2	514/844	De Lacharriere; Olivier et al.
US 6277387 B1	USPAT	20010821	Use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF .alpha. antagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained	424/401	424/70.1; 514/844; 514/859; 514/937; 514/944	De Lacharriere; Olivier et al.
US 6267972 B1	USPAT	20010731	Cosmetic/pharmaceutical compositions comprising .beta.-adrenergic agonists/substance P antagonists	424/401	424/45; 424/450; 424/451; 424/464; 424/489; 424/49; 424/62; 424/65; 424/70.1;	Breton; Lionel et al. □

					424/73; 514/844	
US 6262050 B1	USPAT	20010717	Topical composition containing capsazepine	514/213.0 1		De Lacharriere; Olivier
US 6241993 B1	USPAT	20010605	Therapeutic/cosmetic compositions comprising bradykinin antagonists for treating sensitive human skin	424/401	424/43; 424/489; 424/49; 424/70.1; 514/844; 514/846; 514/936; 514/944	Breton; Lionel et al.
US 6169069 B1	USPAT	20010102	Therapeutic/cosmetic compositions comprising CGRP antagonists for treating the eyes or eyelids	514/2	514/844	De Lacharriere; Olivier et al.
US 6168809 B1	USPAT	20010102	Alkaline-earth metal salt for the treatment of ocular or palpebral pruritus and dysesthesia	424/677	424/665; 514/912	De Lacharriere; Olivier et al.
US 6106846 A	USPAT	20000822	Use of at least one thermal spring water from Vichy as a substance P antagonist	424/401	424/49; 424/70.1; 514/844; 514/846; 514/886; 514/887; 514/912; 514/937; 514/944	Breton; Lionel et al.
US 6048855 A	USPAT	20000411	Topical composition containing capsazepine	514/213.0 1	424/401	De Lacharriere; Olivier et al.
US 6019967 A	USPAT	20000201	Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin	424/130.1	424/401; 424/47; 424/489; 424/70.1; 514/2; 514/844; 514/846; 514/937; 530/300; 530/387.1	Breton; Lionel et al.
US 5993833 A	USPAT	19991130	Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological	424/401	424/70.1; 514/25; 514/263.31; 514/339; 514/352; 514/382;	De Lacharriere; Olivier et al.

			composition		514/840; 514/859; 514/937; 514/944	
US 5989568 A	USPAT	19991123	Cosmetic/dermatological skin care compositions comprising S-DHEA	424/401	424/450; 424/489; 514/844; 514/937; 514/944	Breton; Lionel et al.
US 5976559 A	USPAT	19991102	Compositions and methods for treating wrinkles and/or fine lines of the skin	424/401	514/844; 514/846; 514/944	De Lacharriere; Olivier et al.
US 5972892 A	USPAT	19991026	Topical composition containing a substance P antagonist	514/15	514/210.01; 514/293; 514/305; 514/315; 514/410; 514/416; 514/422; 514/423; 514/426; 514/438; 514/461; 514/613; 514/617; 514/646; 514/663	De Lacharriere; Olivier et al.
US 5958432 A	USPAT	19990928	Cosmetic/pharmaceutical compositions comprising .beta.-adrenergic agonists/substance P antagonists	424/401	424/450; 424/451; 424/464; 424/47; 424/489; 424/49; 424/701; 514/844; 514/845; 514/846; 514/847; 514/861; 514/863; 514/885; 514/903; 514/912; 514/944	Breton; Lionel et al.
US 5935586 A	USPAT	19990810	Therapeutic/cosmetic compositions comprising CGRP antagonists for	424/401	424/130.1; 424/139.1; 424/198.1;	De Lacharriere; Olivier et al.

			treating disease states of the skin		424/450; 424/451; 424/490; 514/2	
US 5932215 A	USPAT	19990803	Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discrete erythema	424/158.1	424/130.1; 424/133.1; 424/145.1; 424/185.1; 424/198.1; 424/401; 424/809; 514/2	de Lacharriere; Olivier et al.
US 5902805 A	USPAT	19990511	Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same	514/159	424/401; 514/161; 514/460; 514/844; 514/845; 514/847; 514/848; 514/852; 514/859; 514/861; 514/863; 514/887; 514/969	Breton; Lionel et al.
US 5900257 A	USPAT	19990504	Cosmetic/pharmaceutical compositions comprising lanthanide manganese, tin and/or yttrium salts as substance P antagonists	424/639	424/600; 424/617; 424/646; 424/650; 424/677; 424/715; 424/718; 424/722	Breton; Lionel et al.
US 5900242 A	USPAT	19990504	Cosmetic/dermatological skin care compositions comprising S-DHEA	424/401	424/450; 424/489; 514/844; 514/937; 514/944	Breton; Lionel et al.
US 5895649 A	USPAT	19990420	Method for treating neurogenic red skin blotches with compositions containing TNF-alpha antagonists	424/130.1	424/520; 424/725; 424/764; 514/2; 514/263.31; 514/338; 514/557; 514/588; 514/738; 514/886;	De Lacharriere; Olivier et al.

					514/887; 514/937; 514/938	
US 5869068 A	USPAT	19990209	Compositions and methods for treating wrinkles and/or fine lines of the skin	424/401	514/844; 514/846; 514/944	De Lacharriere; Olivier et al.
US 5866168 A	USPAT	19990202	Dermatological/pharmaceutical compositions comprising lanthanide, manganese, tin, zinc, yttrium, cobalt, barium and/or strontium salts as substance P antagonists	424/639	424/600; 424/617; 424/646; 424/650; 424/677; 424/715; 424/718; 424/722	De Lacharriere; Olivier et al.
US 5858024 A	USPAT	19990112	Composition for dyeing keratin fibres containing a substance P antagonist	8/408	424/70.6; 8/405; 8/406; 8/407; 8/423; 8/563; 8/618; 8/637.1	De Lacharriere; Olivier et al.
US 5851556 A	USPAT	19981222	Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained	424/639	424/600; 424/617; 424/646; 424/650; 424/677; 424/715; 424/718; 424/722	Breton; Lionel et al.
US 5849312 A	USPAT	19981215	Therapeutic/cosmetic compositions comprising bradykinin antagonist for treating sensitive human skin	424/401	424/43; 424/489; 424/49; 424/70.1; 514/844; 514/846; 514/936; 514/944	Breton; Lionel et al.
US 5824650 A	USPAT	19981020	Topical composition containing a substance P antagonist	514/15	514/167; 514/210.03; 514/252.04; 514/293; 514/305; 514/315; 514/410; 514/416; 514/422; 514/423; 514/426; 514/438;	De Lacharriere; Olivier et al.

					514/461; 514/613; 514/617; 514/646; 514/663	
US 5803095 A	USPAT	19980908	Permanent wave compositions comprising substance P/CGRP antagonists	132/204	132/200; 132/202; 132/203; 424/70.2	De Lacharriere; Olivier et al.
US 5795574 A	USPAT	19980818	Use of an extract from a non-photosynthetic filamentous bacterium and composition containing it	424/115	424/158.1; 424/617; 424/630; 424/639; 424/641; 424/642; 424/646; 424/650; 424/681; 424/74; 514/15; 514/17; 514/183; 514/44; 514/443; 514/783	Breton; Lionel et al.
US 5788956 A	USPAT	19980804	Antiperspirant compositions comprising substance P antagonists	424/65	424/400; 424/401; 424/404; 424/66; 424/67; 424/68	De Lacharriere; Olivier et al.
US 5744156 A	USPAT	19980428	Use of a substance P antagonist for the treatment of skin reddening of neurogenic origin	424/445	424/443	De Lacharriere; Olivier et al.
US 5733558 A	USPAT	19980331	Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same	424/401	514/159; 514/460; 514/852; 514/863	Breton; Lionel et al.
US 5730998 A	USPAT	19980324	Use of a substance P antagonist for the treatment of pruritus, ocular and/or palpebral pain and ocular or	424/443	424/423; 424/451; 424/464	de Lacharriere; Olivier et al.

			palpebral dysaesthesia			
US 5714155 A	USPAT	19980203	Ethylenediamine derivative in a cosmetic or dermatological composition, and composition containing in particular a product having an irritant side effect	424/401	514/844; 514/846; 514/937; 514/938; 514/944	De Lacharriere; Olivier et al.
US 5679360 A	USPAT	19971021	Substance P antagonist for the treatment of lichens, prurigo, pruritus	424/401	424/434; 424/436; 424/450; 424/489; 514/2; 514/844; 514/937; 514/944	de Lacharriere; Olivier et al.
US 5658581 A	USPAT	19970819	Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained	424/401	424/701; 514/840; 514/859; 514/937; 514/944	De Lacharriere; Olivier et al.